The EMA anticipates that the ability to access scientific advice will foster innovation among medical device manufacturers.

European Medicines Agency (EMA), in close collaboration with the European Commission, has established a standard procedure ...

The European Medicines Agency (EMA) has joined the hordes of users abandoning Elon Musk's X.com (formerly Twitter) and will ...

The European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer ...

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines for approval at its ...

Approval from EMA to expand the Phase III trial FLAMINGO-01 into Europe enhances the company's research capabilities and potential market reach. The activation of approximately 110-115 clinical ...

The USD/CAD pair encounters initial resistance at the nine-day EMA of 1.4362, followed by the 14-day EMA at 1.4373. A break ...

Additionally, the 14-day Relative Strength Index (RSI) is positioned slightly below the 50 level, suggesting a bearish bias is active. However, the NZD/USD pair remains slightly below the nine-day ...

Greenwich LifeSciences (GLSI), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is ...